Cargando…
Engineering RNA for Targeted siRNA Delivery and Medical Application()
RNA engineering for nanotechnology and medical applications is an exciting emerging research field. RNA has intrinsically defined features on the nanometre scale and is a particularly interesting candidate for such applications due to its amazing diversity, flexibility and versatility in structure a...
Autores principales: | , , , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Elsevier B.V.
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2906696/ https://www.ncbi.nlm.nih.gov/pubmed/20230868 http://dx.doi.org/10.1016/j.addr.2010.03.008 |
_version_ | 1782184044648202240 |
---|---|
author | Guo, Peixuan Coban, Oana Snead, Nicholas M. Trebley, Joe Hoeprich, Steve Guo, Songchuan Shu, Yi |
author_facet | Guo, Peixuan Coban, Oana Snead, Nicholas M. Trebley, Joe Hoeprich, Steve Guo, Songchuan Shu, Yi |
author_sort | Guo, Peixuan |
collection | PubMed |
description | RNA engineering for nanotechnology and medical applications is an exciting emerging research field. RNA has intrinsically defined features on the nanometre scale and is a particularly interesting candidate for such applications due to its amazing diversity, flexibility and versatility in structure and function. Specifically, the current use of siRNA to silence target genes involved in disease has generated much excitement in the scientific community. The intrinsic ability to sequence-specifically downregulate gene expression in a temporally- and spatially controlled fashion has led to heightened interest and rapid development of siRNA-based therapeutics. Although methods for gene silencing have been achieved with high efficacy and specificity in vitro, the effective delivery of nucleic acids to specific cells in vivo has been a hurdle for RNA therapeutics. This article covers different RNA-based approaches for diagnosis, prevention and treatment of human disease, with a focus on the latest developments of non-viral carriers of siRNA for delivery in vivo. The applications and challenges of siRNA therapy, as well as potential solutions to these problems, the approaches for using phi29 pRNA-based vectors as polyvalent vehicles for specific delivery of siRNA, ribozymes, drugs or other therapeutic agents to specific cells for therapy will also be addressed. |
format | Text |
id | pubmed-2906696 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2010 |
publisher | Elsevier B.V. |
record_format | MEDLINE/PubMed |
spelling | pubmed-29066962010-08-04 Engineering RNA for Targeted siRNA Delivery and Medical Application() Guo, Peixuan Coban, Oana Snead, Nicholas M. Trebley, Joe Hoeprich, Steve Guo, Songchuan Shu, Yi Adv Drug Deliv Rev Article RNA engineering for nanotechnology and medical applications is an exciting emerging research field. RNA has intrinsically defined features on the nanometre scale and is a particularly interesting candidate for such applications due to its amazing diversity, flexibility and versatility in structure and function. Specifically, the current use of siRNA to silence target genes involved in disease has generated much excitement in the scientific community. The intrinsic ability to sequence-specifically downregulate gene expression in a temporally- and spatially controlled fashion has led to heightened interest and rapid development of siRNA-based therapeutics. Although methods for gene silencing have been achieved with high efficacy and specificity in vitro, the effective delivery of nucleic acids to specific cells in vivo has been a hurdle for RNA therapeutics. This article covers different RNA-based approaches for diagnosis, prevention and treatment of human disease, with a focus on the latest developments of non-viral carriers of siRNA for delivery in vivo. The applications and challenges of siRNA therapy, as well as potential solutions to these problems, the approaches for using phi29 pRNA-based vectors as polyvalent vehicles for specific delivery of siRNA, ribozymes, drugs or other therapeutic agents to specific cells for therapy will also be addressed. Elsevier B.V. 2010-04-30 2010-03-15 /pmc/articles/PMC2906696/ /pubmed/20230868 http://dx.doi.org/10.1016/j.addr.2010.03.008 Text en Copyright © 2010 Elsevier B.V. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Article Guo, Peixuan Coban, Oana Snead, Nicholas M. Trebley, Joe Hoeprich, Steve Guo, Songchuan Shu, Yi Engineering RNA for Targeted siRNA Delivery and Medical Application() |
title | Engineering RNA for Targeted siRNA Delivery and Medical Application() |
title_full | Engineering RNA for Targeted siRNA Delivery and Medical Application() |
title_fullStr | Engineering RNA for Targeted siRNA Delivery and Medical Application() |
title_full_unstemmed | Engineering RNA for Targeted siRNA Delivery and Medical Application() |
title_short | Engineering RNA for Targeted siRNA Delivery and Medical Application() |
title_sort | engineering rna for targeted sirna delivery and medical application() |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2906696/ https://www.ncbi.nlm.nih.gov/pubmed/20230868 http://dx.doi.org/10.1016/j.addr.2010.03.008 |
work_keys_str_mv | AT guopeixuan engineeringrnafortargetedsirnadeliveryandmedicalapplication AT cobanoana engineeringrnafortargetedsirnadeliveryandmedicalapplication AT sneadnicholasm engineeringrnafortargetedsirnadeliveryandmedicalapplication AT trebleyjoe engineeringrnafortargetedsirnadeliveryandmedicalapplication AT hoeprichsteve engineeringrnafortargetedsirnadeliveryandmedicalapplication AT guosongchuan engineeringrnafortargetedsirnadeliveryandmedicalapplication AT shuyi engineeringrnafortargetedsirnadeliveryandmedicalapplication |